Global Age-Related Macular Degeneration (AMD) Market to Reach US$ 20.88 Billion by 2033, Driven by Innovative Treatments and Rising Awareness

Introduction

According to Renub Research Recent Report Age-Related Macular Degeneration (AMD) Market is poised for steady growth over the next decade, expanding from US$ 11.42 billion in 2024 to US$ 20.88 billion by 2033, at a CAGR of 6.94% during the forecast period 2025–2033. The market growth is driven by the rising prevalence of AMD due to aging populations, lifestyle-related risk factors, improved diagnostic tools, growing awareness, and the introduction of novel treatments and therapies.

AMD is a degenerative eye condition affecting the macula, the central portion of the retina responsible for sharp and detailed vision. It primarily impairs central vision, which is critical for reading, driving, facial recognition, and color perception. While the precise pathophysiology of AMD remains complex, advancements in genetic research have identified several variants influencing disease development. Clinically, AMD is categorized as dry (atrophic/non-neovascular) or wet (exudative/neovascular), with each type having unique characteristics and treatment requirements.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Market Growth Drivers

1. Innovative Treatment Options

The AMD market is expanding rapidly thanks to novel therapies, including anti-VEGF (vascular endothelial growth factor) treatments, which prevent abnormal blood vessel formation in the retina. These therapies have significantly improved patient outcomes, especially for wet AMD, stabilizing or enhancing vision for many individuals. Additionally, ongoing research in gene therapy offers promising approaches for targeting the genetic causes of AMD. The introduction of advanced products such as Eylea, Lucentis, and Beovu has broadened the treatment landscape, providing multiple options for patients and clinicians alike. The continuous development of groundbreaking therapies is expected to sustain market growth throughout the forecast period.

2. Increasing Awareness

Public awareness campaigns by healthcare organizations, ophthalmologists, and patient advocacy groups have played a key role in promoting early detection of AMD. As individuals become more knowledgeable about symptoms, risk factors, and available treatments, they are more likely to seek timely screenings. Early detection can prevent severe vision loss and improve the efficacy of therapies. This increased awareness, combined with access to healthcare services, is accelerating demand for diagnostic and therapeutic solutions, particularly in developing regions.

3. Rising Healthcare Investments

Increased funding for ophthalmology and retinal research is accelerating the development of innovative diagnostic and therapeutic solutions for AMD. Public and private investments are supporting clinical trials, research initiatives, and advanced technology adoption, enabling faster introduction of new products to the market. These developments not only improve patient outcomes but also enhance the efficiency of healthcare systems, further driving market expansion globally.

Challenges in the Market

High Treatment Costs

One of the primary challenges facing the AMD market is the high cost of treatment, particularly for anti-VEGF therapies that require repeated injections over extended periods. Such expenses can impose a financial burden on patients and healthcare systems, especially in low- and middle-income countries. Limited insurance coverage and the need for continuous monitoring further increase costs, which may discourage some patients from seeking or continuing treatment.

Lack of Early Diagnosis

AMD often progresses slowly, and early symptoms may go unnoticed. Many patients seek medical care only after significant vision loss occurs, reducing the effectiveness of available treatments. Limited access to routine eye screenings, particularly among high-risk populations, contributes to delayed diagnosis and avoidable vision impairment, highlighting the need for enhanced awareness and proactive healthcare strategies.

Regional Insights

United States

The U.S. dominates the AMD market due to an aging population, advanced healthcare infrastructure, and widespread adoption of innovative therapies. Anti-VEGF treatments, combined with modern diagnostic technologies, have significantly improved patient outcomes for wet AMD. Despite challenges such as high treatment costs and limited options for dry AMD, the market continues to expand, driven by ongoing research and product launches.

Germany

Germany is a leading market in Europe, supported by a strong healthcare system and increasing awareness of eye health. The prevalence of AMD, particularly wet AMD, is rising with an aging population. Advanced diagnostic tools and access to therapies like anti-VEGF injections contribute to positive treatment outcomes. Challenges include treatment costs and limited options for dry AMD, but consistent investment in research and healthcare infrastructure ensures continued market growth.

India

India's AMD market is growing due to a rapidly aging population and increasing awareness of eye health. Urban areas are witnessing higher AMD prevalence, though access to advanced diagnostics and treatments remains limited in rural regions. Anti-VEGF therapy is the primary treatment for wet AMD, but high costs and restricted healthcare infrastructure pose challenges. Government initiatives to expand access to healthcare and rising demand for affordable treatments are expected to support market growth in the coming years.

Saudi Arabia

The AMD market in Saudi Arabia is expanding due to improved healthcare infrastructure and increasing awareness of age-related eye conditions. Anti-VEGF treatments are becoming more accessible in urban centers, although high costs and limited availability in rural regions remain concerns. Growing demand for specialist ophthalmic care, advanced diagnostic tools, and government initiatives to enhance healthcare services are anticipated to drive market expansion in the region.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Disease Type

Dry Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

By Product

Eylea

Lucentis

Beovu

Others

By Distribution Channel

Hospital Pharmacy

Specialty Pharma

Online Pharmacy

Country-Wise Analysis

North America: United States, Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey

Asia Pacific: India, China, Japan, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Players

The global AMD market features leading pharmaceutical and healthcare companies, focusing on innovation, treatment development, and strategic expansion. Major players include:

Hoffmann-La Roche Ltd.

Bayer AG

AbbVie

GSK Plc

Novartis AG

Regeneron Pharmaceuticals

Bausch Health Companies Inc.

Alimera Sciences Inc.

These companies are advancing the AMD market through research, product development, partnerships, and clinical trials, contributing to improved patient outcomes and wider access to treatments.

Future Outlook

The AMD market is expected to experience steady growth between 2025 and 2033, supported by technological advancements, increased awareness, and the development of novel therapies. Emerging treatments, combined with government initiatives and growing healthcare investments, are likely to enhance patient care and expand market reach globally.

With the prevalence of AMD rising alongside an aging global population, the demand for effective diagnostics, innovative therapies, and early intervention strategies is expected to surge. As new treatment modalities and gene therapies are introduced, the AMD market is poised to transform patient outcomes, prevent vision loss, and improve quality of life for millions of individuals worldwide.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.